Patents by Inventor Jeong-Ah Kim
Jeong-Ah Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240246961Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: January 23, 2024Publication date: July 25, 2024Inventors: Sung-Ku CHOI, Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Kyu-Sic JANG, Ju-Young JUNG, Soo-Jin LEE
-
Patent number: 11970493Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: GrantFiled: October 4, 2021Date of Patent: April 30, 2024Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
-
Publication number: 20240102081Abstract: Described herein is an in vitro genetic rescue assay for identifying a functionally defective DDX41 variant which includes identifying a DEAD-Box Helicase 41 (DDX41) variant of uncertain significance (VUS), infecting a first Ddx41+/? cell with a retrovirus expressing the DDX41-VUS, infecting a second Ddx41+/? cell with a retrovirus expressing a wild type control DDX41, growing the first and second infected cells in culture for a period of time and quantitating mRNA expression of a DDX41-regulated transcript in both the first and second infected cells after the period of time, calculating a differential expression of the DDX41-regulated transcript for the first infected cell compared the second infected cell, and identifying the DDX41-VUS as the functionally defective DDX41 variant wherein a change in the differential expression is 1.5-fold or greater. The identified functionally defective DDX41 variants can be used in methods of monitoring a patient for the development/progression of myeloid malignancy.Type: ApplicationFiled: September 21, 2023Publication date: March 28, 2024Inventors: Emery Bresnick, Jeong-Ah Kim
-
Publication number: 20240041888Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: ApplicationFiled: October 2, 2023Publication date: February 8, 2024Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, DONG-Keun SONG, Yoon-Suk LEE, Ju-Young JUNG
-
Patent number: 11806350Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: GrantFiled: November 17, 2021Date of Patent: November 7, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun Kim, Jeong-Ah Kim, An-Na Moon, Dong-Keun Song, Yoon-Suk Lee, Ju-Young Jung
-
Patent number: 11787812Abstract: The present disclosure provides androgen receptor (AR) and phosphodiesterase 5 (PDE-5) inhibitor compounds of the formula (I): and compositions including said compounds. The compounds can provide dual functionality for inhibiting AR and inhibiting PDE-5. The present disclosure also provides methods of using said compounds and compositions for inhibiting AR and PDE-5 in a biological system or biological sample. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: GrantFiled: December 10, 2021Date of Patent: October 17, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Yoonsuk Lee, Kyung Sun Kim, Jeong-Ah Kim, Anna Moon, Dongkeun Song, Juyoung Jung, Jun-Su Ban, Soo-Jin Lee
-
Publication number: 20230159534Abstract: The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease.Type: ApplicationFiled: November 19, 2020Publication date: May 25, 2023Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Ju-Young JUNG, Soo-Jin LEE
-
Publication number: 20230076637Abstract: The present invention relates to: a composition for delivering a viral antigen-derived CD8+ T cell antigen epitope or a peptide comprising same to the cytoplasm of a target cell to thereby present the epitope or peptide to major histocompatibility complex class I (MHC-1), which is an antigen-presenting molecule on the cell surface; a composition comprising same; and a use thereof.Type: ApplicationFiled: February 5, 2021Publication date: March 9, 2023Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Yong Sung KIM, Jeong-Ah KIM, Keunok JUNG, Seyoung LEE, Min-Jeong SON
-
Publication number: 20220380376Abstract: The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases.Type: ApplicationFiled: May 10, 2022Publication date: December 1, 2022Inventors: Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Ju-Young JUNG, Soo-Jin LEE
-
Publication number: 20220194948Abstract: The present disclosure provides androgen receptor (AR) and phosphodiesterase 5 (PDE-5) inhibitor compounds and compositions including said compounds. The compounds can provide dual functionality for inhibiting AR and inhibiting PDE-5. The present disclosure also provides methods of using said compounds and compositions for inhibiting AR and PDE-5 in a biological system or sample. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: December 10, 2021Publication date: June 23, 2022Inventors: Yoonsuk LEE, Kyung Sun KIM, Jeong-Ah KIM, Anna MOON, Dongkeun SONG, Juyoung JUNG, Jun-Su BAN, Soo-Jin LEE
-
Publication number: 20220152034Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: ApplicationFiled: November 17, 2021Publication date: May 19, 2022Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, Dong-Keun SONG, Yoon-Suk LEE, Ju-Young JUNG
-
Publication number: 20220154128Abstract: An electroporation apparatus comprising an elongated hollow member in order to provide a uniform electric field during electroporation, wherein specifically, electroporation is carried out by applying electric pulses through a couple of electrodes from both end parts of the elongated hollow member, after the hollow member is charged with fluid specimen including cells and material which would be injected into the cells.Type: ApplicationFiled: September 27, 2021Publication date: May 19, 2022Inventors: Jun-Keun CHANG, Keun-Chang CHO, Chan-II CHUNG, Young-Shik SHIN, Jeong-Ah KIM, Neon-Cheol JUNG
-
Publication number: 20220153746Abstract: The present disclosure provides uses of phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and uses of compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase via donation of NO from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of PKG. The compounds and compositions find use in the treatment of a variety of eye diseases.Type: ApplicationFiled: November 8, 2021Publication date: May 19, 2022Inventors: Yoon-Suk LEE, Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, Dong-Keun SONG, Ju-Young JUNG
-
Publication number: 20220106311Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: October 4, 2021Publication date: April 7, 2022Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
-
Patent number: 11130936Abstract: An electroporation apparatus comprising an elongated hollow member in order to provide a uniform electric field during electroporation, wherein specifically, electroporation is carried out by applying electric pulses through a couple of electrodes from both end parts of the elongated hollow member, after the hollow member is charged with fluid specimen including cells and material which would be injected into the cells.Type: GrantFiled: January 12, 2018Date of Patent: September 28, 2021Assignee: LIFE TECHNOLOGIES HOLDINGS PTE LIMITEDInventors: Jun-Keun Chang, Keun-Chang Cho, Chan-Il Chung, Young-Shik Shin, Jeong-Ah Kim, Neon-Cheol Jung
-
Publication number: 20200283711Abstract: The present invention relates to a three-dimensional cell culture container. A cell culture container according to the present invention may include: a barrier part composed of two or more pillars (110) provided on the top side of the lower plate; an upper plate (130) which finishes an opened end portion of the barrier part; and one or more cell sample injection guide parts (220) provided in one side of the upper plate.Type: ApplicationFiled: December 20, 2017Publication date: September 10, 2020Applicants: KOREA BASIC SCIENCE INSTITUTE, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Jeong Ah KIM, Young Hye KIM, Yeong Jun YU, Seok CHUNG, Ji Hun YANG
-
Publication number: 20200276328Abstract: The present invention relates to a composition for inhibiting regulatory T cell immunosuppression, containing a fusion protein comprising a peptide that binds specifically to neuropilin 1 (NRP1). The fusion protein comprising the peptide that binds specifically to neuropilin 1 according to the present invention can reduce the proportion of regulatory T cells among CD4+ T cells in tumor tissue and inhibit the activity of regulatory T cells that infiltrated into tumor tissue, thereby down-regulating immunosuppression in the tumor tissue without causing systemic toxicity. Thus, the fusion protein can exhibit a high effect on tumor treatment.Type: ApplicationFiled: September 7, 2018Publication date: September 3, 2020Inventors: Yong Sung Kim, Ye Jin Kim, Keunok Jung, Jeong-Ah Kim
-
Publication number: 20200196803Abstract: A pop-up valve according to an embodiment of the present invention includes a head portion; and a foreign matter catching prevention device that is provided in a lower portion of the head portion, in which the foreign matter catching prevention device includes a body portion that is coupled to a bottom of the head portion; a protruding jaw that is formed radially in an outer circumference of the body portion and whose upper surface is in close contact with the head portion; and a first guide vane that extends downward from a bottom of the protruding jaw so as to be perpendicular to the protruding jaw and is located on one side of a second guide vane of a guide device which is coupled to an inside of a drain pipe.Type: ApplicationFiled: October 20, 2017Publication date: June 25, 2020Applicant: SEONGJIN CO., LTD.Inventors: Jong Phil KIM, Jeong Ah KIM
-
Publication number: 20200181897Abstract: The washbasin pop-up valve according to an embodiment of the present invention comprises: a head part for opening/closing a drain; and a cover for foreign-substance sticking prevention, which has a width corresponding to the drain and extends downwards from the downside of the head part.Type: ApplicationFiled: October 20, 2017Publication date: June 11, 2020Applicant: SEONGJIN CO., LTD.Inventors: Jong Phil KIM, Jeong Ah KIM
-
Patent number: RE50241Abstract: An electroporation apparatus comprising an elongated hollow member in order to provide a uniform electric field during electroporation, wherein specifically, electroporation is carried out by applying electric pulses through a couple of electrodes from both end parts of the elongated hollow member, after the hollow member is charged with fluid specimen including cells and material which would be injected into the cells.Type: GrantFiled: July 13, 2023Date of Patent: December 24, 2024Assignee: Life Technologies Holdings PTE Ltd.Inventors: Jun-Keun Chang, Keun-Chang Cho, Chan-Il Chung, Young-Shik Shin, Jeong-Ah Kim, Neon-Cheol Jung